Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Chemo in Metastatic Pulmonary LCNEC
NCT06418087Phase 2Recruiting
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- May 2022
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Efficacy of the combination at 1 year. Started May 2022; status: recruiting.
02
Drugs
durvalumab
03
Conditions
Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC)
Beyond the preview
Go deeper on NCT06418087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06418087.